Dean J Mitchell
CIK 1199297 · President and CEO · last filed 2026-09-24
Dean J Mitchell is a President and CEO who has filed 112 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for TBPH, was dated Sep 24, 2026. Across all open-market trades the lifetime net is +$591.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $8.1M across reported positions. 26 SEC filings were submitted jointly with INTREXON CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
345 PARK AVE
NEW YORK, NY 10164
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) Delisted | Director | 6,009 | $17.03 | $102.3K | $0 | 13 | 2026-09-24 |
| PRAX | Director | 18,622 | $268.31 | $5.00M | $87.0K | 9 | 2026-06-12 |
| PGEN | Director | 503,183 | $6.09 | $3.06M | $35.2K | 13 | 2024-03-18 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 0 | $31.23 | $0 | $125.1K | 42 | 2024-02-12 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | — | $2.65 | — | $0 | 3 | 2023-06-13 |
| PRECIGEN, INC. (XON) Delisted | Director | 49,661 | — | — | $91.6K | 12 | 2019-03-26 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Director | 4,932 | — | — | $0 | 5 | 2011-12-07 |
| Talecris Biotherapeutics Holdings Corp. (TLCR) Delisted | Director | 3,019 | — | — | $0 | 2 | 2010-04-05 |
| ALPHARMA INC (ALO) Delisted | President and CEO | 80 | — | — | $252.5K | 8 | 2008-12-31 |
| MGI PHARMA INC (MOGN) Delisted | Director | 3,887 | — | — | $0 | 1 | 2007-05-09 |
Recent Filings
112 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Disp (D) | −97,213 | $0 | EDGAR |
| 2026-06-16 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +6,009 | $0 | EDGAR |
| 2026-06-12 | PRAX | Grant (A) | +1,371 | $0 | EDGAR |
| 2025-09-25 | PRAX | Exer (M) | +12,251 | $484.0K | EDGAR |
| 2025-06-27 | PRAX | Grant (A) | — | $0 | EDGAR |
| 2025-05-21 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +10,649 | $0 | EDGAR |
| 2024-06-06 | PRAX | Grant (A) | — | $0 | EDGAR |
| 2024-05-10 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +10,537 | $0 | EDGAR |
| 2024-04-05 | — | Disp (D) | — | $0 | |
| 2024-03-18 | PGEN | Grant (A) | +39,510 | $56.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.